Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy.

Powell MA, Ghamande S, Hanker LC, Black D, Raaschou-Jensen N, Gilbert L, Cibula D, Secord AA, Oaknin A, Holloway RW, Mathiesen HF, Buscema J, Kristeleit R, Sharma S, Boere IA, Slomovitz B, Gennigens C, Coleman RL, Heitz F, Barlin JN, Mavrichev S, Berek J, Bermejo-Pérez MJ, Weberpals J, Savarese A, Maret S, Yablonski K, Schroyer R, Austin L, Valabrega G, Nøttrup T

Open source

DOI: 10.1016/j.ijgc.2026.104774
Published: 2026 Aug
Container: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ijgc.2026.104774,
  title = {Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy.},
  author = {Powell MA and Ghamande S and Hanker LC and Black D and Raaschou-Jensen N and Gilbert L and Cibula D and Secord AA and Oaknin A and Holloway RW and Mathiesen HF and Buscema J and Kristeleit R and Sharma S and Boere IA and Slomovitz B and Gennigens C and Coleman RL and Heitz F and Barlin JN and Mavrichev S and Berek J and Bermejo-Pérez MJ and Weberpals J and Savarese A and Maret S and Yablonski K and Schroyer R and Austin L and Valabrega G and Nøttrup T},
  year = {2026},
  journal = {International journal of gynecological cancer : official journal of the International Gynecological Cancer Society},
  doi = {10.1016/j.ijgc.2026.104774},
  url = {https://doi.org/10.1016/j.ijgc.2026.104774}
}

RIS

TY  - JOUR
TI  - Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy.
AU  - Powell MA
AU  - Ghamande S
AU  - Hanker LC
AU  - Black D
AU  - Raaschou-Jensen N
AU  - Gilbert L
AU  - Cibula D
AU  - Secord AA
AU  - Oaknin A
AU  - Holloway RW
AU  - Mathiesen HF
AU  - Buscema J
AU  - Kristeleit R
AU  - Sharma S
AU  - Boere IA
AU  - Slomovitz B
AU  - Gennigens C
AU  - Coleman RL
AU  - Heitz F
AU  - Barlin JN
AU  - Mavrichev S
AU  - Berek J
AU  - Bermejo-Pérez MJ
AU  - Weberpals J
AU  - Savarese A
AU  - Maret S
AU  - Yablonski K
AU  - Schroyer R
AU  - Austin L
AU  - Valabrega G
AU  - Nøttrup T
PY  - 2026
JO  - International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
DO  - 10.1016/j.ijgc.2026.104774
UR  - https://doi.org/10.1016/j.ijgc.2026.104774
ER  -

APA

MA, P., S, G., LC, H., D, B., N, R., L, G., D, C., AA, S., A, O., RW, H., HF, M., J, B., R, K., S, S., IA, B., B, S., C, G., RL, C., F, H., JN, B., S, M., J, B., MJ, B., J, W., A, S., S, M., K, Y., R, S., L, A., G, V., & T, N. (2026). Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy.. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. https://doi.org/10.1016/j.ijgc.2026.104774

Source records

pubmed · retrieved 2026-09-25T20:03:19.449Z